Doliver Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.46M | Buy |
274,328
+200,000
| +269% | +$1.79M | 0.67% | 23 |
|
|
2025
Q1 | $557K | Hold |
74,328
| – | – | 0.16% | 96 |
|
|
2024
Q4 | $559K | Sell |
74,328
-6,672
| -8% | -$50.2K | 0.16% | 91 |
|
|
2024
Q3 | $616K | Hold |
81,000
| – | – | 0.17% | 83 |
|
|
2024
Q2 | $501K | Hold |
81,000
| – | – | 0.14% | 91 |
|
|
2024
Q1 | $411K | Hold |
81,000
| – | – | 0.12% | 107 |
|
|
2023
Q4 | $485K | Hold |
81,000
| – | – | 0.15% | 91 |
|
|
2023
Q3 | $573K | Hold |
81,000
| – | – | 0.17% | 79 |
|
|
2023
Q2 | $570K | Hold |
81,000
| – | – | 0.17% | 84 |
|
|
2023
Q1 | $676K | Hold |
81,000
| – | – | 0.21% | 75 |
|
|
2022
Q4 | $930K | Hold |
81,000
| – | – | 0.31% | 55 |
|
|
2022
Q3 | $1.02M | Hold |
81,000
| – | – | 0.38% | 45 |
|
|
2022
Q2 | $857K | Hold |
81,000
| – | – | 0.3% | 60 |
|
|
2022
Q1 | $1.32M | Sell |
81,000
-19,000
| -19% | -$309K | 0.42% | 43 |
|
|
2021
Q4 | $1.52M | Hold |
100,000
| – | – | 0.48% | 34 |
|
|
2021
Q3 | $1.44M | Buy |
+100,000
| New | +$1.44M | 0.48% | 34 |
|